Predicting Pathological Complete Regression with Haematological Markers During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

被引:28
作者
Lee, Joo Ho [1 ,2 ]
Song, Changhoon [1 ]
Kang, Sung-Bum [3 ]
Lee, Hye Seung [4 ]
Lee, Keun-Wook [5 ]
Kim, Jae-Sung [1 ]
机构
[1] Seoul Natl Univ, Bundang Hosp, Dept Radiat Oncol, Coll Med, 82 Gumi Ro 173beon Gil, Seongnam 13620, South Korea
[2] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Radiat Oncol, Coll Med, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Surg, Bundang Hosp, Seongnam, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Dept Pathol, Coll Med, Seongnam, South Korea
[5] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, South Korea
基金
新加坡国家研究基金会;
关键词
Rectal cancer; platelet/lymphocyte ratio; haematological markers; chemoradiotherapy; complete regression; SYSTEMIC INFLAMMATORY RESPONSE; DIFFUSION-WEIGHTED MRI; PREOPERATIVE CHEMORADIOTHERAPY; CHEMORADIATION; PET/CT; RATIO;
D O I
10.21873/anticanres.13067
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study evaluated the efficacy of haematological markers for predicting the pathological complete regression (pCR) during and after neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer (LARC). Patients and Methods: A total of 297 patients with LARC underwent neoadjuvant CRT followed by surgical resection. Complete blood counts (CBCs) were performed before CRT, 3 weeks after the start of CRT (intratherapy), and 4 weeks after CRT. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) were calculated using the serial CBC test. The ratio of change in PLR (cPLR) and NLR (cNLR) was calculated as the increase from the pre-therapy value to intra-therapy or post-therapy value divided by the pre-therapy value. Chi-square and t-test for univariate analysis and multivariate logistic regression were performed to identify significant predictors for pCR. Receiver operating characteristic (ROC) analysis was used to compare predictive values. Results: The overall rate of pCR was 15.9%. Pre-therapy high haemoglobin and low NLR; intra-therapy high PLR, high NLR, high cPLR, and high cNLR; and post-therapy low white blood cell count (WBC), high haemoglobin, and high cPLR were significantly associated with pCR. In multivariate logistic regression, pretherapy high haemoglobin [odds ratio (OR)=1.500, p=0.016], high intra-therapy PLR (OR=1.006, p=0.011), high intra-therapy cPLR (OR=4.948, p< 0.001), and low posttherapy WBC (OR=0.639, p=0.003) were significant predictors for pCR. ROC analysis showed that high intratherapy cPLR was the most accurate predictor of pCR (area under the curve=0.741). Conclusion: Changes of PLR during neoadjuvant CRT for LARC are significant predictors of pCR.
引用
收藏
页码:6905 / 6910
页数:6
相关论文
共 50 条
  • [31] Neoadjuvant chemoradiotherapy for locally advanced rectal cancer: The debate continues
    De Felice, Francesca
    Musio, Daniela
    Izzo, Luciano
    Tombolini, Vincenzo
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 6 (12) : 438 - 440
  • [32] A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer
    Fratte, Chiara Dalle
    Mezzalira, Silvia
    Polesel, Jerry
    De Mattia, Elena
    Palumbo, Antonio
    Buonadonna, Angela
    Palazzari, Elisa
    De Paoli, Antonino
    Belluco, Claudio
    Canzonieri, Vincenzo
    Toffoli, Giuseppe
    Cecchin, Erika
    [J]. ONCOLOGY RESEARCH, 2020, 28 (09) : 847 - 855
  • [33] Locally advanced rectal cancer: post-chemoradiotherapy ADC histogram analysis for predicting a complete response
    Cho, Seung Hyun
    Kim, Gab Chul
    Jang, Yun-Jin
    Ryeom, Hunkyu
    Kim, Hye Jung
    Shin, Kyung-Min
    Park, Jun Seok
    Choi, Gyu-Seog
    Kim, See Hyung
    [J]. ACTA RADIOLOGICA, 2015, 56 (09) : 1042 - 1050
  • [34] Predicting the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Soluble Immune Checkpoints
    Ari, Aziz
    Sevik, Husnu
    Sevinc, Mert Mahsuni
    Tatar, Cihad
    Buyukasik, Kenan
    Surel, Aziz Ahmet
    Idiz, Ufuk Oguz
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2024, 39 (03) : 247 - 254
  • [35] Nomogram Predicting Overall Survival of Resected Locally Advanced Rectal Cancer Patients with Neoadjuvant Chemoradiotherapy
    Song, Jianyuan
    Chen, Zhuhong
    Huang, Daxin
    Wu, Yimin
    Lin, Zhuangbin
    Chi, Pan
    Xu, Benhua
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 7375 - 7382
  • [36] Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors
    Sun, Yanwu
    Wu, Xuejing
    Zhang, Yiyi
    Lin, Huiming
    Lu, Xingrong
    Huang, Ying
    Chi, Pan
    [J]. EJSO, 2019, 45 (07): : 1225 - 1231
  • [37] The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer
    Daniel, E. S.
    Gibbs, P.
    Guerrieri, M.
    Faragher, I.
    [J]. COLORECTAL DISEASE, 2014, 16 (10) : 783 - 787
  • [38] A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
    Li, Yi
    Wang, Ji
    Ma, Xiaowei
    Tan, Li
    Yan, Yanli
    Xue, Chaofan
    Hui, Beina
    Liu, Rui
    Ma, Hailin
    Ren, Juan
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2016, 12 (08): : 1022 - 1031
  • [39] Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancer
    Peng, Jianhong
    Lin, Junzhong
    Qiu, Miaozhen
    Wu, Xiaojun
    Lu, Zhenhai
    Chen, Gong
    Li, Liren
    Ding, Peirong
    Gao, Yuanhong
    Zeng, Zhifan
    Zhang, Huizhong
    Wan, Desen
    Pan, Zhizhong
    [J]. CLINICS, 2016, 71 (08) : 449 - 454
  • [40] Serum miR-143 levels predict the pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
    Hiyoshi, Yukiharu
    Akiyoshi, Takashi
    Inoue, Ramu
    Murofushi, Keiko
    Yamamoto, Noriko
    Fukunaga, Yosuke
    Ueno, Masashi
    Baba, Hideo
    Mori, Seiichi
    Yamaguchi, Toshiharu
    [J]. ONCOTARGET, 2017, 8 (45) : 79201 - 79211